UBE2F-SAG–Mediated RHEB Neddylation Drives mTORC1 in Liver Cancer

Study Background and Research Question

Neddylation is a key post-translational modification that regulates protein activity, stability, and localization through the covalent attachment of the ubiquitin-like molecule NEDD8 to lysine residues on target proteins. While neddylation of cullin family proteins and subsequent regulation of cullin-RING ligase (CRL) activity has been extensively characterized, the modification of non-cullin substrates and its impact on major signaling pathways in oncogenesis remains less understood. The mechanistic target of rapamycin complex 1 (mTORC1) is a master regulator of cell growth, metabolism, and autophagy, and is frequently hyperactivated in hepatocellular carcinoma (HCC). RHEB, a small GTPase, is the principal activator of mTORC1, but whether RHEB itself is regulated by neddylation had not been previously defined. The central research question addressed by Zhang et al. (2025) is whether RHEB undergoes neddylation, which enzymes mediate this modification, and how this affects mTORC1 activity and liver tumorigenesis.

Key Innovation from the Reference Study

The reference study provides the first direct evidence that RHEB is a non-cullin substrate for NEDD8 conjugation, mediated specifically by the E2 enzyme UBE2F and the E3 ligase SAG. This discovery expands the known substrate repertoire of the UBE2F-SAG axis beyond canonical cullin-5 targets and uncovers a new layer of mTORC1 regulation. The identification of a single lysine residue (K169) in RHEB that is essential for neddylation and functional activation links post-translational modification of RHEB to altered subcellular localization, increased GTP-loading, and enhanced mTORC1 signaling.

Methods and Experimental Design Insights

Zhang et al. utilized a combination of in vitro, cell-based, and in vivo approaches to dissect the role of RHEB neddylation. Key methodological highlights include:

• CRISPR/Cas9-mediated gene editing to generate Ube2f knockout (KO) cell lines and mouse models, enabling loss-of-function studies.
• Co-immunoprecipitation and in vitro neddylation assays to confirm direct modification of RHEB by UBE2F and SAG.
• Mass spectrometry to map the neddylation site to lysine 169 of RHEB.
• Functional assays (cell proliferation, cell cycle, autophagy markers) to assess the consequences of UBE2F depletion.
• Liver-specific Ube2f KO in Pten-deficient mice to model the impact on steatosis and tumorigenesis in vivo.
• Immunohistochemical analyses and survival correlation in human HCC samples to link UBE2F and mTORC1 activity to clinical outcomes.

The study also employed classic protein purification and detection workflows, utilizing tagged constructs and affinity-based methods to isolate and characterize modified RHEB, highlighting the importance of robust tags for post-translational modification research.

Core Findings and Why They Matter

The central findings of Zhang et al. can be summarized as follows:

• RHEB is neddylated at K169 by UBE2F and SAG: Biochemical assays confirmed direct NEDD8 conjugation.
• Neddylation enhances RHEB function: Modification increases RHEB's affinity for GTP and its localization to lysosomes, both critical for mTORC1 activation.
• UBE2F depletion reduces mTORC1 activity: Loss of UBE2F leads to decreased cell growth, cell cycle arrest, and induction of autophagy, indicating that neddylation is required for normal mTORC1 function.
• In vivo, Ube2f knockout attenuates liver tumorigenesis: In a Pten-deficient mouse model, loss of Ube2f suppressed steatosis and tumor formation in an mTORC1-dependent manner.
• Clinical relevance: High UBE2F expression and mTORC1 activity correlate with poor survival in HCC patients.

These results position the UBE2F-SAG-RHEB axis as a potential therapeutic target in liver cancer and metabolic disease. By directly linking neddylation of a key mTORC1 regulator to cancer progression, the study provides new molecular insights relevant for both fundamental cell biology and translational oncology.

Comparison with Existing Internal Articles

Several internal resources discuss the technical challenges and solutions for studying post-translational modifications and mTORC1 signaling. For example, the article "X-press Tag Peptide: Precision N-terminal Leader Peptide for Protein Purification" highlights the necessity of reliable N-terminal leader peptides for affinity purification and detection of recombinant proteins in complex modification studies. This aligns with the reference study's use of tagged RHEB constructs and affinity purification workflows to dissect neddylation events, emphasizing the value of robust detection systems such as the X-press Tag Peptide for experimental reproducibility.

Additionally, "X-press Tag Peptide: Precision N-terminal Leader for Protein Purification" discusses how high-solubility tag peptides and specific epitope recognition (e.g., Anti-Xpress antibody detection) streamline studies of signaling pathways like mTORC1 and neddylation. The technical approaches in Zhang et al.'s study—such as affinity purification using ProBond resin and immunodetection—are well-supported by these principles, demonstrating the practical overlap between methodological advances and cutting-edge signaling research.

Limitations and Transferability

While the findings of Zhang et al. are robust, several limitations should be noted:

• Model specificity: The in vivo work focuses on liver-specific Ube2f knockout in the context of Pten deficiency; effects in other genetic backgrounds or tissue types remain to be explored.
• Therapeutic translation: While the UBE2F-SAG axis is presented as a therapeutic target, further validation in preclinical and clinical settings is required to assess safety and efficacy.
• Broader substrate scope: The study focuses on RHEB as a non-cullin substrate; whether additional non-cullin proteins are similarly regulated by UBE2F-SAG neddylation warrants further investigation.

Nevertheless, the mechanistic principles are likely transferable to studies of other neddylation targets and signaling cascades, especially those involving post-translational modifications that integrate metabolic and proliferative signals in cancer.

Protocol Parameters

• RHEB neddylation assay: Utilize co-expression of tagged RHEB and NEDD8 system components in HEK293 or HCC cell lines for in-cellulo neddylation studies.
• Lysine mutation analysis: Introduce K169R mutation in RHEB constructs to assess site-specific neddylation and functional consequences.
• Affinity purification: Use N-terminal leader peptides, such as X-press Tag Peptide, for recombinant RHEB purification. Employ ProBond resin for immobilized metal affinity chromatography and Anti-Xpress antibody for detection.
• Liver-specific gene knockout: Generate tissue-specific Ube2f knockout using Cre-loxP recombination in mouse models to study in vivo effects.
• Autophagy and mTORC1 readouts: Monitor LC3-II accumulation and phosphorylation of mTORC1 substrates (e.g., S6K1, 4EBP1) via immunoblotting.
• Clinical sample analysis: Correlate UBE2F and mTORC1 activity with patient survival using immunohistochemistry and bioinformatics tools.

Research Support Resources

For researchers aiming to replicate or extend these findings, the choice of protein purification tag is critical for workflow efficiency and detection fidelity. The X-press Tag Peptide (SKU A6010) serves as a high-purity, N-terminal leader peptide designed for affinity purification and sensitive detection of recombinant proteins. Its polyhistidine-Xpress epitope-enterokinase configuration is particularly well-suited for workflows involving affinity purification using ProBond resin and anti-epitope antibody detection, both of which are essential in post-translational modification studies such as neddylation-mTORC1 signaling. According to the product information, the peptide offers high solubility in DMSO and water, robust stability with desiccated storage at -20°C, and HPLC-confirmed purity, supporting reproducible and reliable experimental outcomes.